HARBIN, China, Jan. 4 /PRNewswire-Asia/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company's securities will be listed on NASDAQ Global Select Market effective January 4, 2010.
The NASDAQ Global Select Market, one of the three market tiers at NASDAQ, recognizes the highest financial listing standards in the world, with measures including market value, liquidity and earnings. Qualifying for NASDAQ Global Select Market is a mark of achievement, leadership, credibility, and high ethical standards for companies.
"We are excited to meet the qualifications for inclusion in the NASDAQ Global Select Market," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "We are committed to further improve internal governance, strengthen accountability to build stronger confidence among our valued stakeholders. We look forward to increasing our visibility in the capital markets and to joining the ranks of other companies that meet NASDAQ's highest listing standards."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the inclusion of the Company in the Nasdaq Global Select Market. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Stanley Hao, CFO
Tel: +86-0451-5399-4069
Email: stanleyhao@cski.com.cn
Investor Relations Contact:
CCG Investor Relations
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
Mr. R. Micchelli, Sr. Financial Writer
Tel: +1-646-454-4516
Email: richard.micchelli@ccgir.com